We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.74B
AUM Growth
+$339M
Cap. Flow
-$310M
Cap. Flow %
-11.3%
Top 10 Hldgs %
45.15%
Holding
404
New
120
Increased
93
Reduced
80
Closed
88

Top Buys

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$23.4M
2
XOM icon
ExxonMobil
XOM
+$15.3M
3
PXD
Pioneer Natural Resource Co.
PXD
+$12.1M
4
MRK icon
Merck
MRK
+$9.03M
5
BPMC
Blueprint Medicines
BPMC
+$8.62M

Top Sells

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$53.9M
2
AGN
Allergan plc
AGN
+$33.8M
3
IWM icon
iShares Russell 2000 ETF
IWM
+$24.7M
4
MBLY
Mobileye N.V.
MBLY
+$7.21M
5
MNKD icon
MannKind Corp
MNKD
+$5.7M

Sector Composition

Rank Sector Weight
1 Healthcare 8.27%
2 Energy 1.27%
3 Technology 0.21%
4 Communication Services 0.15%
5 Industrials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PXD
51
DELISTED
Pioneer Natural Resource Co.
PXD
$10.6M 0.39%
+76,273
New +$12.1M
EXAS
52
PUT
DELISTED
Exact Sciences
EXAS
$10.4M 0.38%
+3,491
New +$87.7K
CLDX icon
53
CALL
Celldex Therapeutics
CLDX
$2.79B
$10.3M 0.38%
272
– –
TPST icon
54
Tempest Therapeutics
TPST
$13.9M
$10.3M 0.37%
121
-588
-83% -$53.9M
HRTX icon
55
CALL
Heron Therapeutics
HRTX
$92M
$10.2M 0.37%
3,285
-75
-2% -$1.41K
SGMO
56
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$10.1M 0.37%
9,121
-263
-3% -$3.39K
ZGNX
57
DELISTED
Zogenix, Inc.
ZGNX
$10M 0.37%
745,387
-306,964
-29% -$3.76M
TENX icon
58
Tenax Therapeutics
TENX
$419M
$9.91M 0.36%
84
-4
-5% -$456K
RCPT
59
CALL
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$9.6M 0.35%
505
+25
+5% +$4.13K
HUM icon
60
CALL
Humana
HUM
$46.7B
$9.56M 0.35%
+500
New +$92.8K
MNKD icon
61
CALL
MannKind Corp
MNKD
$1.21B
$9.36M 0.34%
3,291
+490
+17% +$12.5K
UTHR icon
62
CALL
United Therapeutics
UTHR
$26.1B
$9.32M 0.34%
+536
New +$96.4K
IOC
63
DELISTED
Interoil Corporation
IOC
$9.22M 0.34%
153,144
-49,788
-25% -$2.54M
HALO icon
64
CALL
Halozyme
HALO
$9.9B
$9.06M 0.33%
4,014
+512
+15% +$9K
EXAS
65
CALL
DELISTED
Exact Sciences
EXAS
$8.94M 0.33%
+3,007
New +$75.5K
PLUR icon
66
Pluri
PLUR
$18.1M
$8.22M 0.3%
40,771
+38,583
+1,763% +$8.49M
BPMC
67
DELISTED
Blueprint Medicines
BPMC
$8M 0.29%
+301,804
New +$8.62M
NVAX icon
68
PUT
Novavax
NVAX
$1.21B
$7.68M 0.28%
345
+34
+11% +$5.98K
INO icon
69
Inovio Pharmaceuticals
INO
$84.7M
$7.39M 0.27%
+75,500
New +$8.07M
OPK icon
70
CALL
Opko Health
OPK
$1.23B
$7.24M 0.26%
+4,500
New +$70K
RCPT
71
PUT
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$7.2M 0.26%
379
+334
+742% +$55.2K
APC
72
DELISTED
Anadarko Petroleum
APC
$7.1M 0.26%
+90,971
New +$7.88M
NWBO
73
PUT
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$6.81M 0.25%
6,862
+3,310
+93% +$29K
IONS icon
74
CALL
Ionis Pharmaceuticals
IONS
$9.14B
$6.67M 0.24%
1,159
-638
-36% -$40.6K
NBIX icon
75
CALL
Neurocrine Biosciences
NBIX
$18.4B
$6.61M 0.24%
1,383
+95
+7% +$4.03K
1 2
3
4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2015 Portfolio in Review

As of Q2 2015, Sabby Management held 404 positions worth $2.74B, up 14% from $2.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sabby Management withdrew a net $310M in Q2 2015, closing 88 positions and reducing 80 holdings. Its most notable exit was Allergan plc, an estimated $33.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 8.3% of assets, down from 9.4% a quarter earlier, followed by Energy and Technology.

Against the trend, Sabby Management opened a new position in ExxonMobil worth $14.8M.

  • Sabby Management's largest Q2 2015 buy was ExxonMobil: 178,310 shares worth $14.8M.
  • Sabby Management added most to iShares 20+ Year Treasury Bond ETF in Q2 2015, an estimated $23.4M increase.
  • Sabby Management's biggest Q2 2015 reduction was Tempest Therapeutics, cutting an estimated $53.9M.
  • Sabby Management fully exited Allergan plc in Q2 2015, selling an estimated $33.8M.
  • Sabby Management's ten largest holdings make up 45% of its $2.74B portfolio in Q2 2015.
  • Sabby Management opened 120 new positions and closed 88 in Q2 2015.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $2.74B.

Based on Sabby Management's 13F filing for Q2 2015, filed 14 Aug 2015.